Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Aurelien Deside
  • Aurelien Deside

Software: Q1 2025 in review

Following the release of Q1 figures for our software coverage, we provide a quick update on the main takeaways, along with our opinion on the best course of action and hierarchy among them. As expected, the main focus of attention was the current macro environment. Unsurprisingly, the companies tha

Cedric Rossi
  • Cedric Rossi

Mister Spex: headed in the right direction

The call yesterday provided an opportunity for newly-appointed CEO Tobias Krauss to reiterate the main strategic measures of SpexFocus, which aims to stabilise and strengthen the group's operational performance this year and eventually lead to scalable and profitable growth from 2026 onwards. Reass

Clement Genelot
  • Clement Genelot

Ceconomy: CFO appointed as interim CEO

With CEO Karsten Wildberger stepping down to become a federal minister in Germany, Ceconomy has appointed CFO Kai-Ulrich Deissner as interim CEO. In our view, this is the best option to ensure completion of a well-thought FY 2025/26 strategic plan (still not fully priced-in by the consensus and sha

Clement Genelot
  • Clement Genelot

Ahold Delhaize: Europe to make up for US margin erosion this year

Post a strong Q1 print, we have cut our FY25 EBIT and EPS by 2% and 3% respectively, to reflect the reversing USD while a faster European profitability recovery should offset likely US margin erosion fuelled by a dilutive sales mix. PT lifted to EUR39 however, with a lower beta and untouched safe-h

Clement Genelot
  • Clement Genelot

Cheffelo: strong Q1, reassuring FY indications

Following another strong Q1, the commercial and profitability recovery is set to be faster-than-expected with >8% growth and >5% EBIT margin. FY 2025-27 EBIT estimates increased by c.9% and PT from SEK61 to SEK63. Buy reiterated with th business model set to thrive alongside HelloFresh in the

Gregory Ramirez
  • Gregory Ramirez

LECTRA BUY | EUR45 Good resistance Chinese lockdowns; strong orde...

º Q2 results were slightly below expectations, but remained decent despite lockdowns in China New system orders hold up well thanks to automotive Company guidance for 2022 has been tightened toward its mid-point

Thibault Morel
  • Thibault Morel

HMS NETWORKS: HMS Networks 2Q22 results above expectations | CONVICTIO...

HMS NETWORKS - CONVICTION BUY | SEK500 HMS Networks 2Q22 results above expectations 2Q22 sales and new orders above expectations Positive surprise on 2Q22 profitability

Cedric Rossi
  • Cedric Rossi

HUGO BOSS: Successful execution and healthy geo mix lead to raised FY2...

HUGO BOSS - NEUTRAL | EUR68 vs. EUR64 Successful execution and healthy geo mix lead to raised FY22 guidance Strong sales and EBIT beat in Q2 driven by execution… … and low exposure to China’s lockdowns FY22 sales and EBIT guidance revised upwards and we increase our FY22-23 estimates by 7%

Clement Genelot
  • Clement Genelot

ROCHE BOBOIS: Q4 topping expectations with good H1 2022 prospects

ROCHE BOBOIS: Q4 topping expectations with good H1 2022 prospects

Victor Floc’h
  • Victor Floc’h

ONCODESIGN (CORPORATE, TP EUR15) | R&D collaboration signed with TiumB...

ONCODESIGN (CORPORATE, TP EUR15) | R&D collaboration signed with TiumBio in fibrosis

ResearchPool Subscriptions

Get the most out of your insights

Get in touch